Results 231 to 240 of about 14,212 (288)

Efficacy of botulinum toxin type A in the treatment of neurogenic lower urinary tract disfunction due to spinal cord injury

, 2017
Celso Marialva, Mónica Bettencourt, Paulo Vale, João Bastos, Maria da Paz Carvalho, Filipa Faria, Nelson Menezes   +6 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Clinical use of non-a botulinum toxins: Botulinum toxin type C and botulinum toxin type F

Neurotoxicity Research, 2006
Botulinum neurotoxin (BoNT) serotype A is commonly used in the treatment of focal dystonia, but some patients are primarily or become secondarily resistant to it. Consequently, other serotypes have to be used when immuno-resistance is proven. In the literature, patients with focal dystonia have been treated with BoNT serotype F with clinical benefit ...
ELEOPRA R, TUGNOLI V, QUATRALE R, ROSSETTO, ORNELLA, MONTECUCCO, CESARE, DRESSLER D.   +5 more
openaire   +3 more sources

Complications of Botulinum Toxin Type A

Facial Plastic Surgery Clinics of North America, 2007
Introduced over 30 years ago for the treatment of strabismus and blepharospasm, botulinum toxin type A (BTX-A) now has established uses for various therapeutic and cosmetic purposes. Although remarkably safe and effective, BTX-A is a potent toxin. Complications can occur, particularly when used by the inexperienced injectors.
Jean, Carruthers, Alastair, Carruthers
openaire   +2 more sources

Clinical use of non-a botulinum toxins: botulinum toxin type B

Neurotoxicity Research, 2006
Botulinum neurotoxin type B (BT, BT-B) has been used as NeuroBloc/MyoBloc since 1999 for treatment of cervical dystonia, hyperhidrosis, spastic conditions, cerebral palsy, hemifacial spasm, bladder dysfunction, spasmodic dysphonia, sialorrhoea, anal fissures, piriformis syndrome, various pain conditions and cosmetic applications.
D, Dressler, R, Eleopra
openaire   +2 more sources

Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure

Journal of Neurology, 2003
Recently, it was reported that botulinum toxin type B complex (BoNT/B) (NeuroBloc(R), Elan Pharmaceuticals) can produce an adequate therapeutic response in patients with antibody induced failure of botulinum toxin type A complex (BoNT/A) therapy. We wanted to study whether this effect is transient or sustained.
Dirk, Dressler, Hans, Bigalke, Reiner, Benecke   +2 more
openaire   +2 more sources